Axsome Therapeutics, Inc. (LON:0HKF)
123.76
+2.86 (2.36%)
At close: Sep 4, 2025
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $150.04M USD in the quarter ending June 30, 2025, with 72.13% growth. This brings the company's revenue in the last twelve months to $495.03M, up 69.83% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$495.03M
Revenue Growth
+69.83%
P/S Ratio
12.79
Revenue / Employee
$724.79K
Employees
683
Market Cap
4.62B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
Dec 31, 2022 | 50.04M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 671.60M |
Axsome Therapeutics News
- 2 days ago - Wells Fargo Initiates Coverage on AXSM with Overweight Rating | AXSM Stock News - GuruFocus
- 9 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - Benzinga
- 4 weeks ago - Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - Benzinga
- 4 weeks ago - Axsome Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Axsome (AXSM) Q2 Revenue Soars 72% - The Motley Fool
- 4 weeks ago - Axsome Therapeutics GAAP EPS of -$0.97 beats by $0.15, revenue of $150.04M beats by $12.02M - Seeking Alpha